Targeting the future in head and neck cancer-Reference-Cited by-同舟云学术

Targeting the future in head and neck cancer

Published:2009-03 Issue:3 Volume:10 Page:204-205
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Brizel David M

Publisher

Elsevier BV

Subject

Oncology

Reference9 articles.

1. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study;Cohen;Lancet Oncol,2009

2. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study;Nordsmark;Radiother Oncol,2005

3. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularisation and resistance of squamous cell head and neck cancer to chemoradiotherapy;Koukourakis;Clin Cancer Res,2001

4. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis;Kyzas;Clin Cancer Res,2005

5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apatinib potentiates the therapeutic effect of anti‐PD‐1 in locally advanced head and neck cancers;Oral Diseases;2023-10-16

2. A Volumetric Delta TCP Tool to Quantify Treatment Outcome Effectiveness Based on Biological Parameters and Different Dose Distributions;IFMBE Proceedings;2018-05-30

3. Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma;Oncotarget;2016-12-04

4. Hypoxia and Radioresistance in Head and Neck Cancer;Molecular Determinants of Head and Neck Cancer;2014

5. The Role of Antiangiogenic Agents in the Treatment of Head and Neck Cancer;Oncology;2012